Araris Biotech
Araris Biotech AG is a pioneering company specializing in the development of advanced antibody-drug conjugates (ADCs) using proprietary linker technology. Their mission is to create safe, potent, and highly efficacious ADCs with an improved therapeutic index, aiming to make a meaningful difference for cancer patients. The company's vision is to enable tailor-made manufacturing of next-generation ADC candidates that combine safety and potency, leveraging innovative platform technologies like AraLinQ™ and transglutaminase conjugation. Backed by a strong investor syndicate, Araris is committed to transforming targeted cancer therapy through cutting-edge bioconjugation solutions.
Industries
Nr. of Employees
small (1-50)
Araris Biotech
Patents
Products
Pipeline of ADC candidates (preclinical)
A portfolio of antibody-drug conjugate candidates produced using a peptide linker and enzymatic conjugation platform; publicly noted programs target antigens including CD79b and Nectin-4.
Pipeline of ADC candidates (preclinical)
A portfolio of antibody-drug conjugate candidates produced using a peptide linker and enzymatic conjugation platform; publicly noted programs target antigens including CD79b and Nectin-4.
Services
Partnered research to generate novel ADCs using a peptide linker and enzymatic conjugation platform.
Conversion of native or engineered antibodies into homogeneous ADCs via a single-step enzymatic process suitable for scale-up.
Preclinical studies and analytical assessments including efficacy, toxicity comparisons, and stability testing to support candidate selection.
Partnered research to generate novel ADCs using a peptide linker and enzymatic conjugation platform.
Conversion of native or engineered antibodies into homogeneous ADCs via a single-step enzymatic process suitable for scale-up.
Preclinical studies and analytical assessments including efficacy, toxicity comparisons, and stability testing to support candidate selection.
Expertise Areas
- Antibody-drug conjugate (ADC) development
- Enzymatic bioconjugation and transglutaminase chemistry
- Peptide linker chemistry and hydrophilic linker design
- Preclinical pharmacology, toxicology and DMPK
Key Technologies
- Transglutaminase-mediated enzymatic conjugation
- Site-specific conjugation at IgG-Fc Q295
- Peptide-based hydrophilic linkers
- One-step enzymatic ADC conjugation of native antibodies
News & Updates
Araris has entered into a research agreement with Johnson & Johnson to develop next-generation ADCs using their proprietary AraLinQ™ technology, demonstrating enhanced safety and antitumor effects in preclinical studies.
A peer-reviewed scientific article reports that Araris' anti-CD79b ADC demonstrated enhanced stability, reduced toxicity, and greater anti-tumor efficacy preclinically compared to commercial polatuzumab vedotin.
Taiho Pharmaceutical has entered into an agreement to fully acquire Araris Biotech, marking a significant milestone in the company's journey in pioneering the future of ADCs.
Araris has announced a collaboration with Chugai Pharmaceutical to generate novel ADCs using their platform, validating its scalability and precision.
Araris published a new technology for developing ADCs supporting their platform in ChemBioChem.
Araris acquired Innate Pharma’s portfolio of transglutaminase related patents, strengthening its position in ADC development.
Araris has entered into a research agreement with Johnson & Johnson to develop next-generation ADCs using their proprietary AraLinQ™ technology, demonstrating enhanced safety and antitumor effects in preclinical studies.
A peer-reviewed scientific article reports that Araris' anti-CD79b ADC demonstrated enhanced stability, reduced toxicity, and greater anti-tumor efficacy preclinically compared to commercial polatuzumab vedotin.
Taiho Pharmaceutical has entered into an agreement to fully acquire Araris Biotech, marking a significant milestone in the company's journey in pioneering the future of ADCs.
Araris has announced a collaboration with Chugai Pharmaceutical to generate novel ADCs using their platform, validating its scalability and precision.
Araris published a new technology for developing ADCs supporting their platform in ChemBioChem.
Araris acquired Innate Pharma’s portfolio of transglutaminase related patents, strengthening its position in ADC development.